Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer’s Dementia in Individuals With Previous Depression
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Depression is associated with an increased risk of Alzheimer's disease. Research has shown that the selective serotonin reuptake inhibitor (SSRI) citalopram decreases amyloid-β generation and plaque load. The authors evaluated the impact of SSRI treatment on CSF biomarkers and progression from mild cognitive impairment (MCI) to Alzheimer's dementia. METHOD: Data sets from 755 currently nondepressed participants from the longitudinal Alzheimer's Disease Neuroimaging Initiative were evaluated by Kaplan-Meier analysis and analyses of variance and covariance with ApoE4 status and age as covariates. RESULTS: In MCI patients with a history of depression, long-term SSRI treatment (>4 years) was significantly associated with a delayed progression to Alzheimer's dementia by approximately 3 years, compared with short-term SSRI treatment, treatment with other antidepressants, or no treatment and compared with MCI patients without a history of depression. No differences in CSF biomarker levels were observed between treatment groups. CONCLUSIONS: Long-term SSRI treatment may delay progression from MCI to Alzheimer's dementia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The study found that more than 4 years of such treatment was associated with delayed progression to clinically diagnosed Alzheimer's disease.”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [119]
In the citing paper
“and long-term treatment with antidepressants delays the conversion of mild cognitive impairment to Alzheimer’s dementia119.”
From Mechanisms and treatment of late-life depression (2019) · cites this paper as [119]
In the citing paper
“Recent findings suggest that SSRIs may delay the onset of Alzheimer’s dementia119.”
From Mechanisms and treatment of late-life depression (2019) · cites this paper as [119]
Citations
Cites
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Diniz, B. S., Butters, M. A., Albert, S. M., Dew, M. A., & Reynolds, C. F. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.118307 · Cited by 1,290
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975 · cited 1×
“A growing body of evidence points toward a complex role of neuroinflammation in amyloidogenesis, neurodegeneration, and cognitive decline (41).”
Setiawan, E., Wilson, A. A., Mizrahi, R., Rusjan, P. M., Miler, L., Rajkowska, G., Suridjan, I., Kennedy, J. L., Rekkas, P. V., Houle, S., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2427 · Cited by 939 · cited 1×
“Neuroinflammation has also been detected in patients during major depressive episodes (42, 43).”
Effect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.93 · Cited by 572 · cited 1×
“Several randomized and placebocontrolled studies have evaluated the effect of SSRIs on cognition in Alzheimer’s dementia, finding either favorable effects (16, 17), no effects (18–20), or even disadvantageous effects of SSRI treatment (21, 22).”
Modrego, P. J., & Ferrández, J. (2004) · Archives of Neurology · doi:10.1001/archneur.61.8.1290 · Cited by 537 · cited 1×
“This is in contrast to anotherprospectivecohort (30) inwhichahigher rateofMCI progression to Alzheimer’s dementia was found to be associated with depression.”
Banerjee, S., Hellier, J., Dewey, M., Romeo, R., Ballard, C., Baldwin, R., Bentham, P., Fox, C., Holmes, C., Katona, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60830-1 · Cited by 532 · cited 1×
“Several randomized and placebocontrolled studies have evaluated the effect of SSRIs on cognition in Alzheimer’s dementia, finding either favorable effects (16, 17), no effects (18–20), or even disadvantageous effects of SSRI treatment (21, 22).”
Depressive symptoms, cognitive decline, and risk of AD in older persons
Wilson, R. S., Barnes, L. L., Mendes de Leon, C. F., Aggarwal, N. T., Schneider, J. S., Bach, J., Pilat, J., Beckett, L. A., Arnold, S. E., Evans, D. A., et al. (2002) · Neurology · doi:10.1212/wnl.59.3.364 · Cited by 528 · cited 1×
“Other studies have found that the severity of depression at baseline was correlated with risk of developing dementia (31).”
Research works printed but not linked: 1
- Bubu OM, Sleep
Cited by
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
RetractedThe Epidemiology of Alzheimer's Disease Modifiable Risk Factors and Prevention
Zhang, X.-X., Tian, Y., Wang, Z.-T., Ma, Y.-H., Tan, L., & Yu, J.-T. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.15 · Cited by 789
“In addition, treatment with the citalopram for more than 4 years was strongly linked to a 3-year delay in progression from mild cognitive impairment (MCI) to AD (25).”
InfluentialMechanisms and treatment of late-life depression
Alexopoulos, G. S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0514-6 · Cited by 592
Microglia, Lifestyle Stress, and Neurodegeneration
Madore, C., Yin, Z., Leibowitz, J., & Butovsky, O. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.003 · Cited by 311
Depression—an underrecognized target for prevention of dementia in Alzheimer’s disease
Dafsari, F. S., & Jessen, F. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0839-1 · Cited by 312
Metadata
- Authors
- Bartels, C., Wagner, M., Wolfsgruber, S., Ehrenreich, H., Schneider, A., & Initiative, F. T. A. D. N.
- Affiliations
- University of Bonn (DE)
- Venue
- American Journal of Psychiatry
- Published
- 2018-03-01
- Volume
- 175
- Issue
- 3
- Pages
- 232-241
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2768441608
- Semantic Scholar
- 84cf627e767f53e0918c5ac480be02106899308f
- Cited by
- 202
- References
- 50
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 26 · 2023: 26 · 2022: 29 · 2021: 34 · 2020: 15 · 2019: 19 · 2018: 15
- FWCI
- 11.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- DZNE Pub (publishedVersion)
- Max Planck Digital Library (submittedVersion)
- GRO (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- National Institutes of Health (5u01ag024904-10)
- National Institute on Aging (U01-AG-024904)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- selective serotonin reuptake inhibitors, citalopram, mild cognitive impairment, Alzheimer's disease, conversion to dementia, history of depression, cerebrospinal fluid biomarkers, amyloid-beta, APOE ε4, antidepressant treatment duration, Alzheimer's Disease Neuroimaging Initiative
- MeSH terms
- Aged, Alzheimer Disease, Depression, Humans, Risk Factors, Citalopram, Selective Serotonin Reuptake Inhibitors, Kaplan-Meier Estimate, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer’s Dementia in Individuals With Previous Depression. https://app.cochat.ai/papers/10.1176/appi.ajp.2017.17040404
- The paper
- Bartels, C., Wagner, M., Wolfsgruber, S., Ehrenreich, H., Schneider, A., & Initiative, F. T. A. D. N. (2018). Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer’s Dementia in Individuals With Previous Depression. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2017.17040404
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.